Skip to main content
. Author manuscript; available in PMC: 2010 Sep 18.
Published in final edited form as: Vaccine. 2009 Aug 3;27(41):5554–5561. doi: 10.1016/j.vaccine.2009.07.034

Fig. 6.

Fig. 6

Protective efficacy of KKF235 immunization against heterologous LVS challenge. BALB/c mice received a single immunizing dose (106 CFU) of KKF235 or PBS (mock control). Mice were rested for 30 days and then challenged i.n. with 3×104 CFU of LVS (∼10 LD50). Mice were then monitored for survival. Difference in survival between KKF235- and mock- vaccinated mice was significant at a p<0.001.